Draft Pandemic Accord: IP Waivers and Benefits for Sharing Pathogen Information Are In – For Now 17/10/2023 Kerry Cullinan Time-bound waivers of intellectual property (IP) rights and benefits for countries that share information about threatening pathogens are some of the key components of the draft pandemic accord sent to World Health Organization (WHO) member states by the Intergovernmental Negotiating Body (INB) on Monday. These two issues have been major bones of contention in negotiations and […] Continue reading -> Dengue Cases Soar in Americas as Mosquitoes Find New Habitats 02/08/2023 Stefan Anderson The number of dengue cases in the Americas has surpassed three million this year, as climate change makes people more vulnerable to the disease and the world more hospitable to the mosquitoes that carry it. Rising temperatures and shifting rainfall patterns are providing a boon to the Aedis aegypti mosquito, the main carrier of dengue. […] Continue reading -> Unite, Act, Eliminate: Mobilising Africa’s Response Against Neglected Tropical Diseases 14/07/2023 Umaro Sissoco Embaló African leaders must take the lead in the fight against Neglected Tropical Diseases, invest in their control and elimination, and foster cross-border collaboration to achieve the goal of eliminating NTDs as public health concerns by 2030. Neglected Tropical Diseases (NTDs) continue to pose a significant threat to the health and well-being of millions of people […] Continue reading -> DNDi Offers Model for Pandemic Accord Negotiators on How Governments Can Leverage Drug R&D Investment 13/04/2023 Kerry Cullinan When governments invest in drug research and development (R&D) with pharmaceutical companies, they should ensure upfront that these drugs are affordable and widely available – and a global pandemic accord needs to provide high-level guidance on how to do this. This is the view of the Drugs for Neglected Diseases initiative (DNDi), a non-profit group […] Continue reading -> A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Dengue Cases Soar in Americas as Mosquitoes Find New Habitats 02/08/2023 Stefan Anderson The number of dengue cases in the Americas has surpassed three million this year, as climate change makes people more vulnerable to the disease and the world more hospitable to the mosquitoes that carry it. Rising temperatures and shifting rainfall patterns are providing a boon to the Aedis aegypti mosquito, the main carrier of dengue. […] Continue reading -> Unite, Act, Eliminate: Mobilising Africa’s Response Against Neglected Tropical Diseases 14/07/2023 Umaro Sissoco Embaló African leaders must take the lead in the fight against Neglected Tropical Diseases, invest in their control and elimination, and foster cross-border collaboration to achieve the goal of eliminating NTDs as public health concerns by 2030. Neglected Tropical Diseases (NTDs) continue to pose a significant threat to the health and well-being of millions of people […] Continue reading -> DNDi Offers Model for Pandemic Accord Negotiators on How Governments Can Leverage Drug R&D Investment 13/04/2023 Kerry Cullinan When governments invest in drug research and development (R&D) with pharmaceutical companies, they should ensure upfront that these drugs are affordable and widely available – and a global pandemic accord needs to provide high-level guidance on how to do this. This is the view of the Drugs for Neglected Diseases initiative (DNDi), a non-profit group […] Continue reading -> A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Unite, Act, Eliminate: Mobilising Africa’s Response Against Neglected Tropical Diseases 14/07/2023 Umaro Sissoco Embaló African leaders must take the lead in the fight against Neglected Tropical Diseases, invest in their control and elimination, and foster cross-border collaboration to achieve the goal of eliminating NTDs as public health concerns by 2030. Neglected Tropical Diseases (NTDs) continue to pose a significant threat to the health and well-being of millions of people […] Continue reading -> DNDi Offers Model for Pandemic Accord Negotiators on How Governments Can Leverage Drug R&D Investment 13/04/2023 Kerry Cullinan When governments invest in drug research and development (R&D) with pharmaceutical companies, they should ensure upfront that these drugs are affordable and widely available – and a global pandemic accord needs to provide high-level guidance on how to do this. This is the view of the Drugs for Neglected Diseases initiative (DNDi), a non-profit group […] Continue reading -> A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi Offers Model for Pandemic Accord Negotiators on How Governments Can Leverage Drug R&D Investment 13/04/2023 Kerry Cullinan When governments invest in drug research and development (R&D) with pharmaceutical companies, they should ensure upfront that these drugs are affordable and widely available – and a global pandemic accord needs to provide high-level guidance on how to do this. This is the view of the Drugs for Neglected Diseases initiative (DNDi), a non-profit group […] Continue reading -> A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Posts navigation Older posts